It wasn’t about selecting a Canadian company, it’s that a Canadian company was the best-in-class partner for us in terms of level of innovation and quality of the team. We’re excited that we get to leverage all of that expertise that has grown up in Ontario. Integrity, fairness, honesty, and perseverance – four lofty principles on which any company would want to conduct its business practices. But for global pharma giant, Takeda, not only did these values shape its foundation over 230 years ago in Osaka, Japan, they continue to be the driving force behind the multinational’s current-day global operations, its partnerships in 80 countries, and its commitment to delivering transformative medicines to patients all across the world. Takeda’s approach to advancing the research, development and commercialization of medicines across its therapeutic focus areas is simple – they don’t reinvent the wheel. Dr. Christopher Arendt, Oncology Therapeutic Area Unit Head, Takeda “While we have an incredibly resourceful and talented group of drug developers, we recognize that across the world, across the biotechs, the academics, there’s exponentially more innovation happening,” says Dr. Christopher Arendt, Head of Takeda’s Oncology Therapeutic Area Unit. “We felt that the right model for the future of Takeda to stay in that pioneering position would be to find those innovators and figure out how we can work with them to successfully accelerate bringing ground-breaking medicines to patients.” It’s no wonder then why Takeda Canada was officially established in 2009, right here in the province – Ontario is home to one of the most unique and collaborative innovation ecosystems on the planet where business, academia and government work together to drive revolutionary ideas to market. Investment in Ontario-based Turnstone Biologics Takeda’s culture of sharing their expertise and heft as a global pharma leader with cutting-edge innovators has one overarching goal: to improve the quality of life for patients worldwide by developing and delivering life-changing treatments. Takeda Canada’s decision to invest in and collaborate with Ottawa-based Turnstone Biologics is looking to do just that for cancer patients. Takeda and Turnstone are pursuing a cutting-edge modality known as oncolytic viruses, which are engineered to target and kill cancer cells, while triggering a response from the body’s immune system to help attack those cancer cells. Dr. Arendt explains, “Dr. John Bell’s [Turnstone scientific co-founder] reputation as a scientist-founder is among the highest in the world in terms of expertise in oncolytic viruses. We want to bring our drug development expertise to the table and understand how we can complement this incredibly scientifically-deep team, a team that has years and years of experience, to bring transformative medicines forward.” “What excites us so much about this opportunity with Turnstone and to bring an oncolytic virus into a cancer patient therapy setting is that the virus is programmed to home in on that tumour micro-environment, start the attack and release a payload comprised of a number of factors designed to potentiate the immune system.” Takeda has discovered Ontario’s number one advantage in their partnership with Turnstone – its people. Talent abounds in Ontario – with 70% of adults possessing a post-secondary education, and with our welcoming approach to immigration, companies in Ontario benefit from quick and predictable access to highly-skilled talent. Says Dr. Arendt, “Having trained in Canada as a PhD Immunologist funded by Canadian Institutes of Health Research (CIHR) and Natural Sciences and Engineering Research Council of Canada (NSERC), I could not be more proud that Takeda’s deep diligence in assessing the oncolytic virus space led to prioritizing a Canadian biotech as our top partner of choice.” Chemistry at work Adding in Takeda’s own drug developers, scientists, and broader commercial team to the mix has enabled this oncolytic virus program to move forward in the development pipeline with necessary regulatory filings and imminent clinical testing and development. But Takeda knows that it takes a certain element of chemistry between the organizations’ teams to drive success. “What we found in Turnstone is a true thought partner,” says Dr. Arendt. “It’s a group that recognizes their strengths that we admire deeply, and they also recognize areas where an industrial partner can help them build competency and offer important contributions.” It’s chemistry that is paying off. In addition to this first oncolytic virus program, Takeda and Turnstone have four other programs in development in the oncology space, leveraging unique combinations of payloads to address diverse kinds of tumours. Life-changing R&D thrives in Ontario In Ontario, small and medium-sized manufacturers can save up to 50% on their after-tax R&D expenditures. We also have some of the lowest corporate tax rates in North America. Tie in advantages like lower costs to conduct clinical trials, access to our 23 research hospitals and more than a dozen research partnership programs and grants, Takeda, along with other top global pharmaceutical companies find the people, the support and the innovation needed to remain on top of this highly competitive sector. A scientist performs research at a Takeda facility Partnerships like the one forged with Ontario-based Turnstone will drive the future of Takeda, advancements in the broader global sphere of pharmaceuticals and, most importantly to Takeda, the chance to dramatically improve the lives of patients. As such, the hunt for new partners and new opportunities is a continuous process. For Dr. Arendt, one thing will continue to be a constant theme at Takeda: “We will never stop looking for innovation. For us, a sustainable pipeline is such a critical part of the future of the organization. We want to constantly pull programs in to the organization through partnering across the world with academic labs, clinical settings and, of course, biotechs.”
Press ReleaseInvest Ontario supports new biomanufacturing facility in HamiltonInvest Ontario supports new biomanufacturing facility in Hamilton, Canada. Project with OmniaBio Inc. drives global leadership in cell and gene therapy. success storiesCiti chooses its Mississauga site for a new Internal Audit hubCiti's new Internal Audit hub in Mississauga, Ontario, will be instrumental in delivering advanced services to support the bank's increasing global growth. success storiesThe allure of Ottawa, Ontario as a hub for 5GTelecom company Parallel Wireless credits Invest Ottawa for helping them quickly and seamlessly integrate into the city’s thriving tech ecosystem. spotlightsKingston, Ontario—your destination for businessAnchored by multinational giants, homegrown successes and high-growth startups with top talent, Kingston, Ontario, is an ideal location for business success. success storiesOntario-made cybersecurity tech is securing vital data that's at rest, in use and in motionOntario-based CryptoMill’s breakthrough encryption technology is attracting fans among international companies and government agencies. Learn what makes the Toronto-based company… spotlightsACE aims to showcase Ontario’s leadership in automotive innovationOntario is moving quickly and decisively to become a leading global hub for developing and building the cars of the future, and ACE is primed to play a pivotal role. success storiesUniversity of Toronto AV researchers take on winterAutonomous Driving in Adverse Conditions – WinTOR for short -- which aims to teach self-driving cars how to handle whatever winter throws their way. success storiesIrish fintech startup Swoop has landed in Ontario's flourishing entrepreneurial ecosystemSince launching in Ontario, Swoop Canada has struck a chord, building up its Canadian client base to over 500 companies, and is looking at tripling its team within 12 months. “… success storiesHydrostor: reshaping the global energy gridOntario’s an ideal place to start a business, particularly in the green energy space. The R… success storiesOntario's Dalton Pharma Services advances the world's therapeutic drug innovationsSome of the world’s most innovative medicines can be traced back to the labs and manufacturing facilities of Dalton Pharma Services. success storiesEQ Works is revolutionizing how companies understand their customers from its “home base” in TorontoKnowledge is power, but many companies have historically known very little about their customers—at least until data analytics companies like EQ Works came along. success storiesWaabi: leading the way to a self-driving futureOn choosing Toronto, Ontario, thanks to its deep talent pool, good investment environment and diversity